KinDex Pharmaceutical is a Seattle, WA-based biotechnology company formed by the reorganization of KinDex Therapeutics, LLC in parallel with the Series A investment. Led by CEO Jeffrey Bland, Ph.D., the company focuses on discovering and developing molecules that modulate key regulatory networks associated with obesity, inflammation and chronic disease. Its most advanced candidate is KDT501. KinDex raised $5m in Series A funding, with backers that included Polaris Partners. The company intends to use the funds to initiate a planned Phase 2 trial of KDT501 in Type 2 diabetic patients. It also plans to undertake additional preclinical and mechanistic studies in brown fat biology.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2014